Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06 nov. 2024 16h05 HE
|
Prelude Therapeutics, Incorporated
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for...
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
24 oct. 2024 07h30 HE
|
Prelude Therapeutics, Incorporated
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from combination...
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
09 oct. 2024 07h30 HE
|
Prelude Therapeutics, Incorporated
WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the...
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
13 sept. 2024 10h00 HE
|
Prelude Therapeutics, Incorporated
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
09 sept. 2024 07h30 HE
|
Prelude Therapeutics, Incorporated
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude...
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 07h01 HE
|
Prelude Therapeutics, Incorporated
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in...
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
09 juil. 2024 07h30 HE
|
Prelude Therapeutics, Incorporated
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two...
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
03 juin 2024 07h01 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 07h01 HE
|
Prelude Therapeutics, Inc.
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at...
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09 avr. 2024 16h35 HE
|
Prelude Therapeutics, Inc.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...